Cheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress
The stress of an operation may help stray cancer cells survive and settle. A few days of two cheap old drugs around surgery might reduce that risk.
Propranolol plus a COX-2 inhibitor given for days around surgery reduced pro-metastatic molecular signatures in randomised biomarker trials in breast and colorectal cancer, and observational series suggest lower recurrence. No commercial sponsor exists because both drugs are generic, so a publicly funded pragmatic trial is the only route to an answer.
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
Pages like this
not linked directly; found by shared links- IdeaPerioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery
Shares No incentive to repurpose cheap drugs, Metastasis is understood least and studied last, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaStrip the platelet coat off travelling tumour cells in ctDNA-positive patients
Shares Epithelial–mesenchymal transition & drug efflux, No incentive to repurpose cheap drugs, Metastasis is understood least and studied last, MRD / molecular residual disease testing.
- IdeaA public fund and label pathway to trial generic drugs against cancer
Shares No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaMetastasis prevention as a formal indication with its own trials and regulatory pathway
Shares Metastasis is understood least and studied last, MRD / molecular residual disease testing, Colorectal cancer.
- IdeaBlunt the inflammation that wakes sleeping cancer cells
Shares Metastasis is understood least and studied last, MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares Metastasis is understood least and studied last, MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.
- IdeaLosartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3
Shares Epithelial–mesenchymal transition & drug efflux, No incentive to repurpose cheap drugs.
- IdeaSoften the tissue that new metastases need in order to grow
Shares Epithelial–mesenchymal transition & drug efflux, Metastasis is understood least and studied last, HR-positive / HER2-negative breast cancer.